Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials

Journal of Geriatric Psychiatry and Neurology

Volumn 28, Issue 3, 2015, Pages 159-173

  Cummings, Jeffrey ^a   Friedman, Joseph H ^b   Garibaldi, George ^c   Jones, Martin ^d   Macfadden, Wayne ^c   Marsh, Laura ^e,f,g   Robert, Philippe H ^h  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b BROWN UNIVERSITY   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Bridge Medical Consulting Ltd   (United Kingdom)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Alzheimer disease; apathy; Parkinson disease; trial design

Indexed keywords

ANTIDEPRESSANT AGENT;

ALZHEIMER DISEASE; APATHY; ARTICLE; CLINICAL TRIAL (TOPIC); COGNITION; CONCURRENT VALIDITY; DISEASE COURSE; DISEASE SEVERITY; DSM-5; EMOTION; HUMAN; INTERRATER RELIABILITY; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; NURSING HOME PATIENT; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; COMPLICATION; DEPRESSION; DEPRESSIVE DISORDER; MALE; METHODOLOGY; PSYCHOLOGY;

ALZHEIMER DISEASE; APATHY; CLINICAL TRIALS AS TOPIC; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; MALE; PARKINSON DISEASE; RESEARCH DESIGN;

EID: 84940207542     PISSN: 08919887     EISSN: 15525708     Source Type: Journal    
DOI: 10.1177/0891988715573534     Document Type: Article

References (135)

1. Chase TN,. Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment. Neurotox Res. 2011; 19 (2): 266-278.
2. van Reekum R, Stuss DT, Ostrander L,. Apathy: why care? J Neuropsychiatry Clin Neurosci. 2005; 17 (1): 7-19.
3. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP,. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013; 9 (1): 63-75.e2.
4. Parkinsons Disease Foundation; Statistics on Parkinsons 2013. Web site. http://www.pdf.org/en/parkinson-statistics. Accessed February 17, 2015.
5. Aarsland D, Bronnick K, Ehrt U,. Neuropsychiatric symptoms in patients with Parkinsons disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007; 78 (1): 36-42.
6. Dujardin K, Sockeel P, Devos D,. Characteristics of apathy in Parkinsons disease. Mov Disord. 2007; 22 (6): 778-784.
7. Kirsch-Darrow L, Fernandez HH, Marsiske M, Okun MS, Bowers D,. Dissociating apathy and depression in Parkinson disease. Neurology. 2006; 67 (1): 33-38.
8. Levy M, Cummings J, Fairbanks L,. Apathy is not depression. J Neuropsychiatry Clin Neurosci. 1998; 10 (3): 314-319.
9. Oguru M, Tachibana H, Toda K, Okuda B, Oka N,. Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2010; 23 (1): 35-41.
10. Dujardin K, Defebvre L,. Apathy in Parkinsons disease: clinical features, mechanisms and assessment. Rev Neurol (Paris). 2012; 168 (8-9): 598-604.
11. Mortby ME, Maercker A, Forstmeier S,. Apathy: a separate syndrome from depression in dementia? A critical review. Aging Clin Exp Res. 2012; 24 (4): 305-316.
12. Starkstein SE, Jorge R, Mizrahi R, Robinson RG,. A prospective longitudinal study of apathy in Alzheimers disease. J Neurol Neurosurg Psychiatry. 2006; 77 (1): 8-11.
13. McPherson S, Fairbanks L, Tiken S, Cummings JL, Back-Madruga C,. Apathy and executive function in Alzheimers disease. J Int Neuropsychol Soc. 2002; 8 (3): 373-381.
14. Turro-Garriga O, Lopez-Pousa S, Vilalta-Franch J,. A longitudinal study of apathy in patients with Alzheimers disease. Rev Neurol. 2009; 48 (1): 7-13.
15. Benoit M, Andrieu S, Lechowski L, Gillette-Guyonnet S, Robert PH, Vellas B,. Apathy and depression in Alzheimers disease are associated with functional deficit and psychotropic prescription. Int J Geriatr Psychiatry. 2008; 23 (4): 409-414.
16. Kaufer DI, Cummings JL, Christine D,. Assessing the impact of neuropsychiatric symptoms in Alzheimers disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998; 46 (2): 210-215.
17. Drye LT, Scherer RW, Lanctot KL,. Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). Am J Geriatr Psychiatry. 2013; 21 (6): 549-559.
18. Rosler M,. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl. 2002;(127): 20-36.
19. Berman K, Brodaty H, Withall A, Seeher K,. Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatry. 2012; 20 (2): 104-122.
20. Mitchell RA, Herrmann N, Lanctot KL,. The role of dopamine in symptoms and treatment of apathy in Alzheimers disease. CNS Neurosci Ther. 2011; 17 (5): 411-427.
21. Robert PH, Mulin E, Mallea P, David R,. Review: apathy diagnosis, assessment, and treatment in Alzheimers disease. CNS Neurosci Ther. 2010; 16 (5): 263-271.
22. Santangelo G, Trojano L, Barone P, Errico D, Grossi D, Vitale C,. Apathy in Parkinsons disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol. 2012; 27 (4): 501-513.
23. Drijgers RL, Aalten P, Winogrodzka A, Verhey FR, Leentjens AF,. Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review. Dement Geriatr Cogn Disord. 2009; 28 (1): 13-22.
24. Rosenberg PB, Lanctot KL, Drye LT,. Safety and efficacy of methylphenidate for apathy in Alzheimers disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013; 74 (8): 810-816.
25. Clarke DE, Ko JY, Kuhl EA, van Reekum R, Salvador R, Marin RS,. Are the available apathy measures reliable and valid? A review of the psychometric evidence. J Psychosom Res. 2011; 70 (1): 73-97.
26. Brown RG, Pluck G,. Negative symptoms: the €pathology€ of motivation and goal-directed behaviour. Trends Neurosci. 2000; 23 (9): 412-417.
27. Schultz W,. The primate basal ganglia and the voluntary control of behaviour. J Consc Stud. 1999; 6 (8-9): 31-45.
28. Marin RS,. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991; 3 (3): 243-54.
29. Robert P, Onyike CU, Leentjens AF,. Proposed diagnostic criteria for apathy in Alzheimers disease and other neuropsychiatric disorders. Eur Psychiatry. 2009; 24 (2): 98-104.
30. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J,. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44 (12): 2308-2314.
31. Stuss DT, Van Reekum R, Murphy KJ,. Differentiation of States and Causes of Apathy. 1st ed. New York: Oxford University Press; 2000.
32. Robert PH, Clairet S, Benoit M,. The apathy inventory: assessment of apathy and awareness in Alzheimers disease, Parkinsons disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002; 17 (12): 1099-1105.
33. Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, Defebvre L,. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinsons disease. J Neurol Neurosurg Psychiatry. 2006; 77 (5): 579-584.
34. Levy R, Dubois B,. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb. Cortex. 2006; 16 (7): 916-928.
35. Starkstein SE, Leentjens AF,. The nosological position of apathy in clinical practice. J Neurosurg Psychiatr. 2008; 79 (10): 1088-1092.
36. Mulin E, Leone E, Dujardin K,. Diagnostic criteria for apathy in clinical practice. Int J Geriatr Psychiatry. 2011; 26 (2): 158-165.
37. Olin JT, Schneider LS, Katz IR,. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002; 10 (2): 125-128.
38. Aarsland D, Marsh L, Schrag A,. Neuropsychiatric symptoms in Parkinsons disease. Mov Disord. 2009; 24 (15): 2175-2186.
39. Bogart KR,. Is apathy a valid and meaningful symptom or syndrome in Parkinsons disease? A critical review. Health Psychol. 2011; 30 (4): 386-400.
40. Cummings JL,. Depression and Parkinsons disease: a review. Am J Psychiatry. 1992; 149 (4): 443-454.
41. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB,. Recognition and treatment of depression in Parkinsons disease. J Geriatr Psychiatry Neurol. 2003; 16 (3): 178-183.
42. Benoit M, Berrut G, Doussaint J,. Apathy and depression in mild Alzheimers disease: a cross-sectional study using diagnostic criteria. J Alzheimers Dis. 2012; 31 (2): 325-334.
43. Drijgers RL, Dujardin K, Reijnders JS, Defebvre L, Leentjens AF,. Validation of diagnostic criteria for apathy in Parkinsons disease. Parkinsonism Relat Disord. 2010; 16 (10): 656-660.
44. Starkstein SE, Mizrahi E, Capizzano AA, Acion L, Brockman S, Power BD,. Neuroimaging correlates of apathy and depression in Alzheimers disease. J Neuropsychiatry Clin Neurosci. 2009; 21 (3): 259-265.
45. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB,. Behavioral and psychological symptoms of dementia. Front Neurol. 2012; 3: 73.
46. Association AP. Diagnostic and Statistical Manual of Mental Disorders (DSM). 5th ed,. text rev ed. Arlington, VA: American Psychiatric Publishing; 2013.
47. Aalten P, Verhey FR, Boziki M,. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord. 2007; 24 (6): 457-463.
48. Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C,. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry. 2009; 194 (3): 212-219.
49. Njomboro P, Deb S,. Poor dissociation of patient-evaluated apathy and depressive symptoms. Curr Gerontol Geriatr Res. 2012; 2012: 846075.
50. Loewenstein DA, Arguelles S, Bravo M,. Caregivers judgments of the functional abilities of the Alzheimers disease patient: a comparison of proxy reports and objective measures. J Gerontol B Psychol Sci Soc Sci. 2001; 56 (2): P78-P84.
51. Cummings JL,. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997; 48 (5 suppl 6): S10-S16.
52. Kaufer DI, Cummings JL, Ketchel P,. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000; 12 (2): 233-239.
53. de Medeiros K, Robert P, Gauthier S,. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010; 22 (6): 984-994.
54. Marin RS, Biedrzycki RC, Firinciogullari S,. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991; 38 (2): 143-162.
55. Lueken U, Seidl U, Volker L, Schweiger E, Kruse A, Schroder J,. Development of a short version of the Apathy Evaluation Scale specifically adapted for demented nursing home residents. Am J Geriatr Psychiatry. 2007; 15 (5): 376-385.
56. Cubo E, Benito-Leon J, Coronell C, Armesto D,. Clinical correlates of apathy in patients recently diagnosed with Parkinsons disease: the ANIMO study. Neuroepidemiology. 2012; 38 (1): 48-55.
57. Fehnel SE, Bann CM, Hogue SL, Kwong WJ, Mahajan SS,. The development and psychometric evaluation of the Motivation and Energy Inventory (MEI). Qual Life Res. 2004; 13 (7): 1321-1336.
58. Aalten P, de Vugt ME, Jaspers N, Jolles J, Verhey FRJ,. The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables. Int J Ger Psy. 2005; 20 (6): 531-536.
59. Lopez OL, Becker JT, Sweet RA,. Psychiatric symptoms vary with the severity of dementia in probably Alzheimers disease. J Neuropsy Clin Neurosci. 2003; 15 (3): 346-353.
60. Kaufer DI, Cummings JL, Christine D,. Assessing the impact of neuropsychiatric symptoms in Alzheimers disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998; 46 (2): 210-215.
61. Holmes C, Wilkinson D, Dean C,. The efficacy of donepezil in the tretament of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004; 63 (2): 213.
62. Hermann N, Rothenburg LS, Black SE,. Methylphenidate for the treatment of apathy in Alzheimer Disease. Prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008; 28 (3): 296-301.
63. Tariot PN, Cummings JL, Katz IR,. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimers disease in the nursing home setting. J Am Ger Soc. 2001; 49 (12): 1590-1599.
64. McKeith I, Del Ser T, Spano PF,. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000; 356 (9247): 2031-2036.
65. Starkstein SE, Petracca G, Chemerinski E, Kremer J,. Syndromic validity of apathy in Alzheimers disease. Am J Psychiatry. 2001; 158 (6): 872-877.
66. Zhao H, Zhao Z, Huang L, Preter M,. Diagnosis and assessment of apathy in Chinese patients with Alzheimers disease. J Psychosom Res. 2012; 72 (5): 405-407.
67. Starkstein SE, Ingram L, Garau ML, Mizrahi R,. On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry. 2005; 76 (8): 1070-1074.
68. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
69. Zarit SH, Zarit JM,. Instructions for the Burden Interview. Technical Document. University Park, PA: Pennsylvania State University; 1987.
70. Stern Y, Albert SM, Sano M,. Assessing patient dependence in Alzheimers disease. J Gerontol. 1994; 49 (5): M216-M222.
71. Gelinas I, Gauthier L, McIntyre M,. Development of a functional measure for persons with Alzheimers disease: the disability assessment for dementia. Am J Occup Ther. 1999; 53 (5): 471-481.
72. Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N,. Self-reported functioning and well-being in patients with Parkinsons disease: comparison of the Short-form Health Survey (SF-36) and the Parkinsons Disease Questionnaire (PDQ-39). Age Ageing. 1995; 24 (6): 505-509.
73. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R,. The development and validation of a short measure of functioning and well being for individuals with Parkinsons disease. Qual Life Res. 1995; 4 (3); 241-248.
74. Alexopoulos G, Abrams R, Young R, Shamoian CA,. Cornell scale for depression in dementia. Biological Psychiatry. 1998; 23 (3): 271-284.
75. Folstein MR, Folstein SE, McHugh PR,. €Mini-mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12 (3): 189-198.
76. Chaves ML, Camozzato AL, Godinho C,. Validity of the clinical dementia rating scale for the detection and staging of dementia in Brazilian patients. Alzheimer Dis Assoc Disord. 2007; 21 (3): 210-217.
77. Krupp LB, LaRocca NG, Muir-Nash J, Steinbery AD,. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46 (10): 1121-1123.
78. Smets EM, Garssen B, Bonke B, De Haes JC,. The Multidimensional Fatigue Inventory (MFI); psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995; 39 (3): 315-325.
79. Johns MW,. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991; 14 (6): 540-545.
80. Zigmond AS, Snaith RP,. €The hospital anxiety and depression scale€. Acta Psychiatrica Scandinavica. 1983; 67 (6): 361-370.
81. Kummer A, Cardoso F, Teixeira AL,. Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinsons disease. Arq Neuropsiquiatr. 2010; 68 (4): 495-501.
82. de Medeiros K, Robert P, Gauthier S, for the NPI-C Research Group. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychoger. 2010; 22 (6): 984-994.
83. Morozova MA, Beniashvili AG, Lepilkina TA, Rupchev GE,. Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr Danub. 2012; 24 (2): 159-166.
84. Ogasa M, Kimura T, Nakamura M, Guarino J,. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013; 225 (3): 519-530.
85. Priebe S, Savill M, Reininghaus U,. Effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia-a multi-centre randomised controlled trial. BMC Psychiatry. 2013; 13: 26.
86. Onyike CU, Sheppard JM, Tschanz JT,. Epidemiology of apathy in older adults: the Cache County Study. Am J Geriatr Psychiatry. 2007; 15 (5): 365-375.
87. van Vliet D, de Vugt ME, Aalten P,. Prevalence of neuropsychiatric symptoms in young-onset compared to late-onset Alzheimers disease-part 1: findings of the two-year longitudinal NeedYD-study. Dement Geriatr Cogn Disord. 2012; 34 (5-6): 319-327.
88. Vilalta-Franch J, Calvo-Perxas L, Garre-Olmo J, Turro-Garriga O, Lopez-Pousa S,. Apathy syndrome in Alzheimers disease epidemiology: prevalence, incidence, persistence, and risk and mortality factors. J Alzheimers Dis. 2013; 33 (2): 535-543.
89. Waldemar G, Gauthier S, Jones R,. Effect of donepezil on emergence of apathy in mild to moderate Alzheimers disease. Int J Geriatr Psychiatry. 2011; 26 (2): 150-157.
90. Zhang M, Wang H, Li T, Yu X,. Prevalence of neuropsychiatric symptoms across the declining memory continuum: an observational study in a memory clinic setting. Dement Geriatr Cogn Dis Extra. 2012; 2: 200-208.
91. Clarke DE, Reekum R, Simard M, Streiner DL, Freedman M, Conn D,. Apathy in dementia: an examination of the psychometric properties of the apathy evaluation scale. J Neuropsychiatry Clin Neurosci. 2007; 19 (1): 57-64.
92. Clarke DE, van Reekum R, Simard M,. Apathy in dementia: clinical and sociodemographic correlates. J Neuropsychiatry Clin Neurosci. 2008; 20 (3): 337-347.
93. Cramer CK, Friedman JH, Amick MM,. Olfaction and apathy in Parkinsons disease. Parkinsonism Relat Disord. 2010; 16 (2): 124-126.
94. Faerden A, Nesvag R, Barrett EA,. Assessing apathy: the use of the Apathy Evaluation Scale in first episode psychosis. Eur Psychiatry. 2008; 23 (1): 33-39.
95. Lenze EJ, Skidmore ER, Begley AE, Newcomer JW, Butters MA, Whyte EM,. Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry. 2012; 27 (9): 974-980.
96. Marangell LB, Johnson CR, Kertz B, Zboyan HA, Martinez JM,. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. J Clin Psychiatry. 2002; 63 (5): 391-395.
97. Raskin J, George T, Granger RE, Hussain N, Zhao GW, Marangell LB,. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram. J Psychiatr Res. 2012; 46 (5): 667-674.
98. Varanese S, Perfetti B, Ghilardi MF, Di Rocco A,. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinsons disease. PLoS One. 2011; 6 (3): e17846.
99. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A,. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995; 25 (6): 1171-1180.
100. McClintock SM, Husain MM, Wisniewski SR,. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011; 31 (2): 180-186.
101. Fava M, Graves LM, Benazzi F,. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006; 67 (11): 1754-1759.
102. Nelson JC, Portera L, Leon AC,. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry. 2005; 66 (11): 1409-1414.
103. Litvinenko IV, Odinak MM, Mogilnaya VI, Emelin AY,. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinsons disease (an open controlled trial). Neurosci Behav Physiol. 2008; 38 (9): 937-945.
104. Pedersen KF, Alves G, Aarsland D, Larsen JP,. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J Neurol Neruosurg Psychiatry. 2009: 80 (11): 1279-1282.
105. Ahearn DJ, McDonald K, Barraclough M, Leroi I,. An exploration of apathy and impulsivity in Parkinson disease. Curr Gerontol Geriatr Res. 2012; 2012: 390701
106. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell A,. Prevalence and correlates of neuropsychiatric symptoms in Parkinsons disease without dementia. Mov Disord. 2008; 21 (13): 1889-1896.
107. Barone P, Antonini A, Colosimo C, on behalf of the PRIAMO study group. The Priamo study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinsons disease. Mov Disord. 2009; 24 (11): 1641-1649.
108. Goetz CG, Tilley BC, Shaftman SR, on behalf of the Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinsons Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Move Disord. 2008; 23 (15): 2129-2179.
109. Gallagher DA, Goetz CG, Stebbins G, Lees AJ, Schrag A,. Validation of the MDS-UPDRS part 1 for nonmotor symptoms in Parkinsons disease. Mov Disord. 2012: 27 (1): 79-83.
110. Leentjens AFG, Dujardin K, Marsh L,. Apathy and anhedonia rating scales in Parkinsons disease: critique and recommendations. Mov Disord. 2008; 23 (14): 2004-2014.
111. Starkstein S,. Apathy in Parkinsons disease: diagnostic and etiological dilemmas. Mov Disord. 2012: 27 (2): 174-178.
112. Starkstein SE, Merello M,. The Unified Parkinsons Disease Rating Scale: validation study of the mentation, behavior, and mood section. Mov Disord. 2007; 22 (15): 2156-2161.
113. Pedersen KF, Larsen JP, Aarsland D,. Validation of the Unified Parkinsons Disease Rating Scale (UPDRS) section I as a screening and diagnositc instrument for apathy in patients with Parkinsons disease. Parkinsonism Relat Disord. 2008; 14 (3): 183-186.
114. Kirsch-Darrow L, Zahodne LB,. How cautious should we be when assessing apathy with the Unified Parkinsons Disease Rating Scale? Mov Disord. 2009: 24 (5): 684-688.
115. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S,. Depression rating scales in Parkinsons disease: critique and recommendations. Mov Disord. 2007; 22 (8): 1077-1092.
116. Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, Lanctôt KL., Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008; 28 (3): 296-301.
117. Lanctot KL, Chau SA, Herrmann N,. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int Psychogeriatr. 2013; 29 (2): 1-8.
118. Padala PR, Burke WJ, Shostrom VK,. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010; 18 (4): 371-374.
119. Devos D, Moreau C, Delval A, Dujardin K, Defebvre L, Bordet R,. Methylphenidate: a treatment for Parkinsons disease? CNS Drugs. 2013; 27 (1): 1-14.
120. Cummings JL, McRae T, Zhang R,. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006; 14 (7): 605-612.
121. Cummings JL, Nadel A, Masterman D, Cyrus PA,. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimers disease. J Geriatr Psychiatry Neurol. 2001; 14 (2): 101-108.
122. Mega MS, Masterman DM, OConnor SM, Barclay TR, Cummings JL,. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol. 1999; 56 (11): 1388-1393.
123. Zeitzer JM, David R, Friedman L,. Phenotyping apathy in individuals with Alzheimer disease using functional principal component analysis. Am J Geriatr Psychiatry. 2013; 21 (4): 391-397.
124. Liperoti R, Pedone C, Corsonello A,. Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol. 2008; 6 (2): 117-1124.
125. Seitz DP, Gill SS, Herrmann N,. Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. Int Psychogeriatr. 2013; 25 (2): 185-203.
126. Sink KM, Holden KF, Yaffe K,. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005; 293 (5): 596-608.
127. Frakey LL, Salloway S, Buelow M, Malloy P,. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimers disease. J Clin Psychiatry. 2012; 73 (6): 796-801.
128. Hooker K, Bowman SR, Coehlo DP,. Behavioral change in persons with dementia: relationships with mental and physical health of caregivers. J Gerontol B Psychol Sci Soc Sci. 2002; 57 (5): P453-P460.
129. Seitz D, Purandare N, Conn D,. Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review. Int Psychogeriatr. 2010; 22 (7): 1025-1039.
130. Zuidema S, Koopmans R, Verhey F,. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. J Geriatr Psychiatry Neurol. 2007; 20 (1): 41-49.
131. Jorge RE, Starkstein SE, Robinson RG,. Apathy following stroke. Can J Psych. 2010; 55 (6): 350-354.
132. Brodaty H, Sachdev PS, Withall A, Altendorf A, Valenzuela MJ, Lorentz L,. Frequency and clinical, neuropsychological and neuroimaging correlates of apathy following stroke-the Sydney Stroke Study. Psychol Med. 2005; 12 (12): 1707-1716.
133. Mikarni K, Jorge RE, Moser DJ, Jany M, Robinson RG,. Incident apathy during the first year after stroke and its effect on physical and cognitive recovery. Am J Ger Psych. 2013; 21 (9): 848-854.
134. Domecq Garces JP, Wang Z, Elraiyah TA,. Eliciting Patient Perspective in Patient-Centered Outcomes Research: A Meta Narrative Systematic Review. Rochester: Mayo Clinic; 2012: 1-163. http://www.pcori.org/assets/Eliciting-Patient-Perspective-in-Patient-Centered-Outcomes-Research-A-Meta-Narrative-Systematic-Review.pdf. Accessed February 17, 2015.
135. Washington AE, Lipstein SH,. The Patient-Centered Outcomes Research Institute-promoting better information, decisions, and health. New Eng J Med. 2011; 365 (15): e31.